Oruka Therapeutics, Inc. financial data

Symbol
ORKA on Nasdaq
Location
Menlo Park, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2448% % 1.2%
Debt-to-equity 4% % -40%
Return On Equity -27% % 57%
Return On Assets -26% % 37%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 48,409,232 shares 38%
Common Stock, Shares, Outstanding 48,384,150 shares 38%
Entity Public Float $39,700,000 USD 90%
Common Stock, Value, Issued $48,000 USD 37%
Weighted Average Number of Shares Outstanding, Basic 42,095,951 shares 1216%
Weighted Average Number of Shares Outstanding, Diluted 42,095,951 shares 1216%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $0 USD
Research and Development Expense $103,531,000 USD 132%
General and Administrative Expense $18,788,000 USD 80%
Operating Income (Loss) $122,319,000 USD -122%
Nonoperating Income (Expense) $16,307,000 USD 363%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $106,699,000 USD -98%
Earnings Per Share, Basic 2 USD/shares 93%
Earnings Per Share, Diluted 2 USD/shares 93%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $91,253,000 USD -78%
Marketable Securities, Current $257,902,000 USD
Other Assets, Current $537,000 USD -10%
Assets, Current $355,163,000 USD -14%
Property, Plant and Equipment, Net $253,000 USD 58%
Operating Lease, Right-of-Use Asset $1,969,000 USD 110%
Other Assets, Noncurrent $103,000 USD 140%
Assets $509,251,000 USD 23%
Accounts Payable, Current $571,000 USD 137%
Employee-related Liabilities, Current $109,000 USD -43%
Liabilities, Current $20,967,000 USD 16%
Operating Lease, Liability, Noncurrent $1,493,000 USD 77%
Liabilities $22,460,000 USD 19%
Accumulated Other Comprehensive Income (Loss), Net of Tax $185,000 USD
Retained Earnings (Accumulated Deficit) $159,574,000 USD -175%
Stockholders' Equity Attributable to Parent $486,791,000 USD 42%
Liabilities and Equity $509,251,000 USD 23%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $20,869,000 USD -1266%
Net Cash Provided by (Used in) Financing Activities $0 USD
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 545,000,000 shares 0%
Common Stock, Shares, Issued 48,384,150 shares 38%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,528,000 USD 4.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $91,253,000 USD -78%
Deferred Tax Assets, Valuation Allowance $21,317,000 USD -62%
Deferred Tax Assets, Gross $21,501,000 USD -61%
Operating Lease, Liability $1,912,000 USD 94%
Depreciation $16,000 USD
Payments to Acquire Property, Plant, and Equipment $13,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $101,446,000 USD -5%
Lessee, Operating Lease, Liability, to be Paid $2,333,000 USD 79%
Property, Plant and Equipment, Gross $222,000 USD -3.1%
Operating Lease, Liability, Current $419,000 USD 187%
Lessee, Operating Lease, Liability, to be Paid, Year Two $768,000 USD 55%
Lessee, Operating Lease, Liability, to be Paid, Year One $822,000 USD 123%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $421,000 USD 32%
Lessee, Operating Lease, Liability, to be Paid, Year Three $397,000 USD 4.5%
Deferred Tax Assets, Operating Loss Carryforwards $2,260,000 USD
Unrecognized Tax Benefits $1,047,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $304,000 USD
Operating Lease, Payments $63,000 USD 174%
Additional Paid in Capital $643,201,000 USD 62%
Share-based Payment Arrangement, Expense $25,246,000 USD 154%